Pôle de Recherche en Gynécologie, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
J Assist Reprod Genet. 2013 Oct;30(10):1289-99. doi: 10.1007/s10815-013-0065-3. Epub 2013 Aug 29.
To assess the safety of reimplantation of cryopreserved ovarian tissue from advanced-stage breast cancer patients.
Cryopreserved ovarian cortical fragments were obtained from 13 advanced-stage breast cancer patients aged 17-35 years. After thawing, part of the ovarian cortical tissue was grafted to severe combined immunodeficient mice for 6 months. The presence of malignant mammary cells in ovarian tissue was evaluated after thawing as well as after grafting by 1) histology and immunohistochemistry (epithelial membrane antigen, Her2/neu and gross cystic disease fluid protein 15 identification), and 2) detection of the MGB2 gene by qPCR.
No malignant cells were evidenced by histology and immunohistochemistry. None of the mice died during the 6-month grafting period, nor developed macroscopically visible masses. MGB2 gene expression was detected by qPCR and confirmed by sequencing in frozen-thawed ovarian tissue in 4 cases and in grafts in 1 case.
This pilot study is the first to evaluate the risk of contamination of cryopreserved ovarian tissue from advanced-stage breast cancer patients by xenotransplantation for 6 months to immunodeficient mice, associated with more conventional screening methods. Our xenografting results are reassuring, but caution needs to be exercised, as MGB2 gene expression was detected in some cases. Larger numbers of ovarian tissue samples from patients with advanced-stage breast cancer are required to confirm our findings before ovarian tissue transplantation can be contemplated in these patients.
评估晚期乳腺癌患者冷冻卵巢组织再植入的安全性。
从 13 名 17-35 岁的晚期乳腺癌患者中获取冷冻保存的卵巢皮质碎片。解冻后，部分卵巢皮质组织被移植到严重联合免疫缺陷小鼠中 6 个月。解冻后和移植后，通过 1）组织学和免疫组织化学（上皮膜抗原、Her2/neu 和大体囊性疾病液体蛋白 15 鉴定）以及 2）qPCR 检测 MGB2 基因，评估卵巢组织中恶性乳腺细胞的存在。
组织学和免疫组织化学均未发现恶性细胞。在 6 个月的移植期间，没有一只小鼠死亡，也没有出现肉眼可见的肿块。qPCR 检测到 MGB2 基因表达，并在 4 例冷冻解冻卵巢组织和 1 例移植组织中通过测序进行了确认。
这项初步研究首次评估了将晚期乳腺癌患者的冷冻卵巢组织通过异种移植到免疫缺陷小鼠中 6 个月的污染风险，同时结合了更传统的筛查方法。我们的异种移植结果令人放心，但需要谨慎，因为在一些情况下检测到了 MGB2 基因表达。需要更多来自晚期乳腺癌患者的卵巢组织样本来确认我们的发现，然后才能考虑在这些患者中进行卵巢组织移植。
